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Introduction
Angiogenesis is crucial for tumor growth and metastasis. The angiogenic switch refers to a phenotypic change that occurs early in a tumor's development that is necessary for growth beyond 2-3 mm in size. Hypoxia is the trigger for many of the mechanisms by which a tumor induces angiogenesis. For example, hypoxia induces the expression of hypoxia-inducible factor (HIF-1), which in turn up-regulates vascular endothelial growth factor (VEGF) (1) . Another family of pro-angiogenic factors includes the CXC chemokines containing the glutamic acid-leucine-arginine (ELR) motif, which in humans includes CXCL1, CXCL3, CXCL5, and CXCL8 (2) . We and others have described proangiogenic properties of this family of chemokines, which are produced by tumor cells and infiltrating stromal cells in lung cancer and other malignancies (3) (4) (5) (6) . These are largely produced by NF B transcriptional activation, and represent an alternative pathway for the angiogenic switch (7) . Other important factors that promote tumor angiogenesis either directly or indirectly include basic fibroblast growth factor (bFGF), macrophage migration inhibitory factor (MIF), angiopoietin 1, and epidermal growth factor (EGF), among others.
Many studies describe the mechanism by which individual factors promote angiogenesis in vitro or in vivo. Studies of tumor-derived angiogenic factors have typically focused on one particular angiogenic pathway within a given tumor type.
Likewise, many clinical trials employing anti-angiogenic therapies in have focused primarily on blocking one particular anti-angiogenic strategy such as VEGF (8) .
Malignant tumors, however, demonstrate phenotypic variability even within the same histologic subtype. There is no reason to suspect that this variation should not also be present in the angiogenic switch. For example, we have shown that resected non-small cell lung cancer (NSCLC) specimens contain VEGF, as well as ELR+ CXC chemokines, and MIF. Based upon these human data, however, it is not clear whether such differences reflect the inherent variability that one might expect from the study of human tissues.
The question of the variability and plasticity of the angiogenic switch requires further study in a more controlled experimental setting. This variability has important implications for the rational design of anti-angiogenic therapy.
Given these observations, we hypothesize that during tumorigenesis, initial selection pressures or genetic alterations lead to the development of one dominant angiogenic strategy. Furthermore, activation of a particular angiogenic pathway may suppress the expression of other angiogenic factors, as the angiogenic switch relieves the constraints imposed upon a developing tumor by hypoxia and/or nutrient deprivation. In this report, we support our hypothesis with data demonstrating that tumors from human lung cancer specimens express a pattern of angiogenic factors that suggests activation of one dominant factor, or "angiogenic signature" in each tumor. This angiogenic signature depends, in part, on the presence of mutant K-ras. Furthermore, we show that carcinogen-induced murine lung tumors in-vivo, even from within the same mouse, vary in their angiogenic profiles. Finally, we show that the angiogenic "profile" of tumor cells has plasticity and can be altered in the short term in a sponge model of angiogenesis.
This paradigm of variability and plasticity in the angiogenic switch has prognostic and therapeutic implications in NSCLC and other cancers. ELISA. Aqueous tumor and normal lung extracts were subjected to specific ELISA according to our protocol published previously (9) . All of the tissue samples were run in parallel for total protein content (Pierce, Rockford, IL), and results were standardized by expressing values as ng of cytokine per mg total protein. Because the angiogenic CXC chemokines are all of equivalent potency in terms of angiogenic activity and mediate their angiogenic effects via the same receptor (CXC receptor 2), we generated a combined "ELR score" for each of the human tumors (9) , representing the sum of the levels (in ng of cytokine per mg of protein; ng/mg) of all of the measured CXC chemokines bearing the ELR motif (glu-leu-arg, shared by the angiogenic CXC chemokines). That is total levels of IL-8/CXCL8, ENA-78/CXCL5, GRO /CXCL1, and GRO /CXCL3 for human tumors, and murine CXCL1, -2, and 5 for murine tumors.
Materials and Methods

Reagents
Detection of K-ras codon 12 mutations. We used a modification of the method described by Kubrusly et al (10) to detect activating mutations in codon 12 of the K-ras gene in cDNA from a subset of archived tumor specimens. We used the forward PCR In order to generate larger tumors, we euthanized some mice 9 months after NNK, and removed all visible tumors. We homogenized these tumors then sonicated, and filtered the aqueous extracts to perform ELISA for murine angiogenic cytokines. We were not able to generate a sufficient ELISA assay for murine basic FGF, and these tumors were therefore only measured for their levels of mVEGF, as well as mCXCL1, mCXCL2, and mCXCL5, the functional murine equivalents of the human angiogenic CXC chemokines. Results were expressed as ng/mg, and the levels CXC chemokines were summed to determine the "ELR score" as previously described (9).
RNA processing and semi-quantitative real time polymerase chain reaction (RT-PCR).
We isolated RNA using manufacturer instructions provided with Trizol reagent (Invitrogen, Carlsbad, CA). Reverse transcription of mRNA to make cDNA copies was conducted using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA) and following manufacturer's protocols. Semi-quantitative RT-PCR was performed on an ABI PRISM 7000 Sequence Detection System apparatus (Applied Biosystems) using primers and probes as described above, and beta-actin to normalize results. A section of normal lung from an untreated mouse served as the reference value to which all other measurements from tumors were normalized. The PCR reaction was performed in 25-µL volume containing 1 µL of cDNA per reaction. Data were analyzed with the sequence detection system software. Relative gene expression was calculated using the comparative cyclethreshold (C T ) method.
Sponge model of angiogenesis. We used a sponge angiogenesis assay modified from the method described by Fife et al (12) . We shaved the flanks of 6 week old C57/B6 mice and anesthetized them with ketamine 100 mg/kg and xylazine 7.0 mg/kg.
Immediately prior to implantation, we combined 10 6 LLC cells/ml with 2.5 µg/ml of the angiogenic substance of interest (mVEGF or mCXCL1) in serum free media (DMEM).
200 µl of the cell suspension was adsorbed onto to sterile 9 mm diameter polyvinyl alcohol sponge discs (Rippey Corporation, El Dorado Hills, CA). Sponges containing LLC cells in media alone served as controls. In some experiments we used mice deficient in the receptor for angiogenic CXC chemokines, CXCR2 (CXCR2 -/-mice).
Under sterile conditions, a small incision was made and a sponge was inserted in each flank. After 72 hours, we euthanized the animals and removed the sponges. Some sponges were placed immediately in Trizol and homogenized thoroughly, others were placed in 10% neutral buffered zinc-formalin, and a third group was homogenized in antiprotease buffer, filtered, and frozen for later analysis by ELISA. We briefly centrifuged the homogenate and filtered it (2.0 µm) to remove sponge debris. We used the supernatant to isolate mRNA, reverse transcribe to cDNA, and perform semi-quantitative RT-PCR, as described above. The reference for all RT-PCR reactions was LLC cells cultured in vitro. Some of the sponges were homogenized in anti-protease buffer to perform ELISA.
Immunohistochemistry. After removal of mouse lungs, we fixed a portion of tumor in 10% zinc formalin. Paraffin-embedded tissue sections were dewaxed in xylene and rehydrated through graded concentrations of ethanol. Antigen retrieval was performed with 0.1% trypsin/CaCl 2 for 30 min at 37°. Samples were then stained with appropriate primary antibodies for angiogenic factors, as previously described (13) .
Antigens were visualized with Vectastain ABC kits and diaminobenzidine (DAB) as the chromogen (Vector. Burlingame, CA) as suggested by the manufacturer. For all sections, we performed an appropriate control goat IgG.
We administered pimonidazole reagent, 60 mg/kg (Hypoxyprobe-1, Chemicon, Temecula, CA), to select animals 30 minutes prior to euthanasia via tail vein injection.
After euthanasia , we removed the lungs, and fixed/embedded as described above. We performed immunohistochemistry according to the manufacturer's instructions, using
Hypoxyprobe monoclonal antibody (Hypoxyprobe™-1 kit).
Statistics. Graph Pad Prism 3.0 (San Diego, CA) was used for statistical analysis and plotting of results. Differences between groups were analyzed using Student's t test.
For multiple comparisons, we utilized one-way ANOVA with Bonferroni's post-test analysis.
Results
Human NSCLC specimens can be segregated on the basis of the angiogenic factors they express. Using ELISA of tumor homogenate, we measured the tumorassociated levels of angiogenic factors from three different families: vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor, (bFGF), and the ELR-CXC chemokines (the ELR score-see methods) (9) . We chose these based upon previous studies demonstrating the importance of these pathways in mediating lung cancer angiogenesis (9, (14) (15) (16) (17) (18) (19) . Figure 1 compares the expression levels of these angiogenic factors in tumors from 168 patients with non-small cell lung cancer resected at our institution (Demographics in table I). With the exception of 7 out of 168, tumors expressing bFGF did not express ELR positive CXC chemokines (Fig 1A) or VEGF ( Fig   1B, p < 0.0001 by 2) . Consistent with our previously published data (9), we did observe tumors with simultaneous expression of VEGF, and the angiogenic CXC chemokines.
However, when we divided tumors into groups based upon levels of cytokines above (high) and below (low) the median, the frequency of tumors in our cohort with both high VEGF levels and high ELR score (10.1%; Figure 1C ), is less than would be expected by chance alone (25%; p=0.013 by 2 ). This supports our hypothesis that expression of a given angiogenic factor(s) reduces the likelihood of activation of a second pathway to promote angiogenesis. There was no correlation between the histology, stage, smoking status, or gender and the profile of angiogenic factors detected in any given tumor. These data suggest that tumors develop unique "angiogenic signatures" characterized by the expression of a dominant angiogenic factor.
In order to determine if the expression of a dominant angiogenic factor(s) was associated with specific mutations, we determined the presence or absence of activating mutations on codon 12 of the K-ras gene in a subset of tumors, and compared the levels of chemokines (ELR score) and VEGF in groups defined by their K-ras status. Table II demonstrates that the presence of K-ras mutations was associated with lower levels of VEGF (p=0.01), and a trend toward increased levels of the CXC chemokines (the ELR score; p=0.08), suggesting that oncogenic K-ras favors the development of a chemokine predominant angiogenic signature.
Murine lung tumors develop unique angiogenic strategies. To provide further evidence for our hypothesis, we induced lung tumor formation in A/J mice by injection with the tobacco-derived carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-butanone (NNK), at a dose of 10 µmol (2 mg) ( Fig. 2A) . Since hypoxia can be a primary stimulus for an angiogenic response, we first sought to determine whether NNK-induced lung adenomas manifested evidence of hypoxia. Hypoxyprobe, injected into mice shortly prior to sacrifice localized to the central areas of NNK-induced adenomas, where one would expect the presence of a hypoxic environment (Fig 2B) . By contrast, normal murine lung was negative.
Because of the small size of these tumors, we used semi-quantitative real-time PCR to measure levels of the following angiogenic substances: VEGF, basic FGF, and the murine homologues of the ELR-CXC chemokines CXCL1, CXCL2, and CXCL5. The angiogenic switch can be altered in the short term in-vivo. Tumors often develop resistance to cytotoxic therapy, during or after initially successful chemotherapy.
If the angiogenic phenotype displayed similar plasticity, this would have implications for the design of anti-angiogenic therapy. We sought to determine whether the angiogenic phenotype of tumor cells could be altered in vivo. We employed a model that allowed us to influence the angiogenic milieu over a short period of time. LLC cells (1 x 10 6 ) were implanted in a polyvinyl alcohol sponge with the indicated angiogenic factor ("angiogenic stimulus" figure 6 ; 500 ng/sponge) into subcutaneous pockets in C57BL6 mice. At 72 hours sponges were removed, and total RNA was isolated (Trizol). We then determined mRNA expression of VEGF or CXCL1 in response to implantation in vivo. production may seem mutually exclusive, the production of H 2 O 2 by NADPH-oxidases does not require high tensions of oxygen, and is actually activated in response to hypoxia (30) . This H 2 O 2 -mediated activation of NF B was enhanced by the presence of mutant K-ras. Indeed oncogenic K-ras transformation requires a functional NADPH-oxidase (31). Mizukami et al concluded that K-ras mutations favored the expression of the angiogenic factor CXCL8 particularly in the setting of hypoxia (7). This is particularly relevant to our current study, in which the majority of mouse tumors developed an angiogenic signature characterized by predominant expression of angiogenic CXC chemokines, and in which the carcinogen (NNK) promotes tumors by induction of K-ras mutations (32) . Our human tumor data suggest that while the presence of activating Kras mutations does not exclusively predict the predominance of chemokine expression in the angiogenic mechanism of a tumor, there was a trend toward increased chemokine expression in K-ras mutant tumor compared to K-ras wild type tumors. The presence of mutant K-ras did decrease the likelihood of VEGF being highly expressed in these tumors.
A limitation of our study is that we evaluated a limited number of angiogenic factors, relative to the number which are known to affect angiogenesis (33) . However, since our purpose was to determine the diversity of the angiogenic switch, we limited our phenotyping of these tumors to these well characterized angiogenic factors. Our observations support our hypothesis that tumors develop a unique angiogenic signature.
As the availability of pharmacologic inhibitors of angiogenesis increases, it may be prudent for clinical trials of these newer agents to include stratification of patients based upon the angiogenic signatures determined by tissue taken from the tumor. Table II : The presence of mutations in K-ras and levels of VEGF and CXC chemokines (ELR score) in the corresponding tumor from a subset of tumors taken from our database. Tumors with K-ras codon 12 mutations are less likely to express high levels of VEGF, and demonstrate a trend toward increased levels of angiogenic CXC chemokines. 
